Clinical trial · Observational
Active Surveillance for Prostate Cancer With Indolent Features
Prospective Cohort Study of Active Surveillance for Prostate Cancer With Indolent Linical Features
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In patients with prostate cancer with indolent features, disease progrssion may be very slow and in many cases will never become clinically evident during the patient's lifetime. Active surveillance is a continuous process of monitoring disease characteristcs aiming to avoid the morbidity of active therapy in patients with stabe indolent parameters, while offering early detection of disease activity in others who will need active therapy to control their disease. We hypothesize that active surveillance will permit the avoidance of therapy related morbidity in the majority of appropriate patients and will be associated with maintaining their quality of life.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 65 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Men 65 years of age or older who were diagnosed with prostate cancer in the past 3 month prior to inclusion 2. Gleason's score of 6 or less. 3. Clinical T1C per digital rectal exam. 4. Pre biopsy PSA serum level of 6.0ng/ml or less. 5. The presence of cancer in a single biopsy core of at least 8 taken. 6. The presence of cancer in no more than 10% of the length of the core involved. 7. Patient's consent to engage in active surveillance after being informed of the benefits and potential risks of this approach as well as of alternative lines of therapy. 8. Israeli residence with the readiness to be available for the followup schedule. Exclusion Criteria: Patients who do not meet the above eligibility criteria
References
Publications (0)
Data not yet available